Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 16

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
889,000 preferred shares remain authorized but undesignated.

As of September 30, 2025, there were 786,902 shares
of common stock outstanding, 17.488 shares of Series A Preferred Stock, and no shares of Series B Preferred Stock or Series C Preferred
Stock issued and outstanding, and a stock payable balance of $0.

9

During the nine months ended September 30, 2025,
the Company issued a total of 249,994 shares of its common stock under the February 2024 ATM Agreement in return for aggregate net proceeds
of $1,152,686, which takes into account $35,953 in compensation paid to Ascendiant Capital Markets, LLC (“Ascendiant”)
in its role as Sales Agent under the February 2024 ATM Agreement.

At-the-Market Equity Offering Program

On February 14, 2024, the Company entered into
a new At-The-Market Issuance Sales Agreement with Ascendiant (the “February 2024 ATM Agreement”) to sell shares of common
stock for aggregate gross proceeds of up to $6.2 million, which replaced the Company’s prior At-The-Market Issuance Sales Agreement.
Under the February 2024 ATM Agreement, as of September 30, 2025, the Company has issued a total of 249,994 shares of its common stock
in return for aggregate net proceeds of $1,152,686, resulting in $35,953 of compensation paid to Ascendiant. On October 13, 2025, the
Company terminated the February 2024 ATM Agreement. 

Reverse Stock Split

On August 16, 2024, the Company filed with the
Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation, which effectuated, as of August
20, 2024 at 12:01 a.m. Eastern Time, a reverse split of the Company’s common stock at a ratio of one-for-50 (the “August 2024
Reverse Stock Split”).

On November 4, 2024, the Company filed with the
Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation, which effectuated, as of November
7, 2024 at 12:01 a.m. Eastern Time, a reverse split of the Company’s common stock at a ratio of one-for-35 (the “November
2024 Reverse Stock Split